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Abstract
Background: It is well established that asbestos is the most important cause of mesothelioma.
The role of simian virus 40 (SV40) in mesothelioma development, on the other hand, remains
controversial. This potential human oncogene has been introduced into various populations
through contaminated polio vaccines. The aim of this study was to investigate whether the possible
presence of SV40 in various European countries, as indicated either by molecular genetic evidence
or previous exposure to SV40-contaminated vaccines, had any effect on pleural cancer rates in the
respective countries.
Methods: We conducted a Medline search that covered the period from January 1969 to August
2005 for reports on the detection of SV40 DNA in human tissue samples. In addition, we collected
all available information about the types of polio vaccines that had been used in these European
countries and their SV40 contamination status.
Results: Our ecological analysis confirms that pleural cancer mortality in males, but not in females,
correlates with the extent of asbestos exposure 25 – 30 years earlier. In contrast, neither the
presence of SV40 DNA in tumor samples nor a previous vaccination exposure had any detectable
influence on the cancer mortality rate in neither in males (asbestos-corrected rates) nor in females.
Conclusion: Using the currently existing data on SV40 prevalence, no association between SV40
prevalence and asbestos-corrected male pleural cancer can be demonstrated.
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Background
Asbestos is a potent carcinogen and the most important
single cause of mesothelioma, a mostly fatal cancer of the
pleura [1-3]. Only about 20% of mesothelioma cases
occur in non-exposed individuals [4,5]. Previous studies
have shown that mesothelioma mortality rates correlate
with past asbestos consumption rates (defined by produc-
tion minus export plus import) in industrialized countries
[1,6]. During the past 40 to 50 years, asbestos consump-
tion varied considerably in European countries, with low
per capita use in less industrialized countries, such as Bul-
garia, and vast use in ship building and other insulating
industries,e.g.  in the U.K. Since the time lag between
asbestos exposure and tumor development is 30 to 45
years in most cases, the recent increase in mesothelioma
incidence should therefore reflect the intensified use of
asbestos during this particular period [3,7-9]. Indeed, the
production of asbestos peaked worldwide in the late
1970s and early 1980s [10]. Likewise, the mesothelioma
incidence is expected to reach maximum levels between
2010 and 2020 in industrialized countries [6]. About half
of the cases will occur in construction and shipbuilding
workers, as in these professions asbestos exposure was
particularly common [6]. Incidence is much lower in
women, as they were generally, not involved in asbestos-
related activities [11].
The fact that traces of simian virus 40 (SV40) were repeat-
edly demonstrated in a significant proportion of mesothe-
lioma samples led to the notion that this virus may act as
either a co-carcinogen or tumor promoter [12-14]. SV40
was introduced unintentionally into millions of people
via  contaminated poliomyelitis virus vaccines between
1955 and 1963. However, some vaccines produced later
may have not been entirely SV40-free, as evidenced by the
fact that SV40 DNA has been recently detected in archival
polio vaccines produced in 1966 and 1969 by a major
Eastern European manufacturer [15]. SV40 was present in
both the attenuated (oral) polio vaccine (OPV) and the
inactivated polio vaccine (IPV), since formaldehyde treat-
ment, which was used to inactivate the poliomyelitis
virus, failed to inactivate SV40 [12].
SV40 DNA was subsequently detected in human brain
and bone tumors as well as lymphoma samples (reviewed
in [16]). Intriguingly, SV40 causes the same tumor types
in hamsters [4]. The most important step in the process of
carcinogenesis is the inactivation of tumor suppressor p53
and members of the retinoblastoma family of proteins
through the SV40 large T antigen [17]. In addition, other
tumor suppressor genes become methylated and are shut
down. These gene modifications have not only been
observed  in vitro, but also in an analogous fashion in
SV40-positive lymphoma samples [18].
However, it is important to note that SV40 DNA was not
detected in several studies of tumor samples from particu-
lar populations, whereas it was readily detectable in
appropriate control samples from the USA [19,20]. In par-
ticular, SV40 DNA was not detected in mesothelioma,
brain tumor and bone tumor samples from Austria, Fin-
land and Turkey, countries which apparently had never
used contaminated polio vaccines [19-24]. These findings
were therefore taken as evidence that the population-spe-
cific and linked geographic differences were genuine and
that they reflected the heterogeneous use of SV40-contam-
inated polio vaccines in the respective countries [4]. How-
ever, definitive epidemiological proof for the presence or
absence of an association between (past) SV40 exposure
and cancer is lacking so far, mostly because the infected
cohorts can no longer be identified unambiguously [4].
The presence of virus-specific antibodies in serum is a
well-established biomarker of viral infection. Antibodies
to SV40 have been measured in humans by plaque inhibi-
tion neutralization assays and enzyme immunoassays.
However, the studies have been mostly negative or
detected only low levels of SV40 serum antibodies [25-
28]. Cross-reactivity between SV40 and the BK polyoma-
virus has been proposed as an explanation for the detec-
tion of low levels of SV40-reactive antibodies in human
serum samples and may complicate the interpretation of
positive assay results [27]. In a recent population-based
case-control study published by Engels et al. [26] using
competitive assays to analyze SV40-specific reactivity, it
has been shown that an estimate of 1% to 1.6% individu-
als from the U.S. born before 1963 had SV40 specific anti-
bodies, whereas those born later showed no SV40 specific
reactivity. The authors stated that these results point to the
possibility that exposure to SV40 could have led to anti-
body responses that declined over the decades, probably
due to lack of virus replication, and that SV40 seems not
to be a common cause of infection in humans [26].
However, the past exposure of humans to SV40 is
undoubted. We therefore set out to investigate whether
mesothelioma (pleural cancer) incidence and mortality
rates might be higher in those European countries
(including the former Communist countries), in which at
least some circumstantial evidence indicates that a popu-
lation-wide exposure had taken place. For this purpose,
we first investigated to what extent pleural cancer mortal-
ity rates correlate with those of past asbestos use. We then
compared country-specific asbestos consumption and
mesothelioma rates with the appropriate likelihood of
SV40 contamination. To ascertain whether the respective
SV40 exposure was frequent, low or absent in specific
countries, we used data from publications that dealt with
the analysis of SV40 DNA in human tissue samples. In
addition, we also collected all the available informationOrphanet Journal of Rare Diseases 2006, 1:44 http://www.OJRD.com/content/1/1/44
Page 3 of 12
(page number not for citation purposes)
about which type of poliomyelitis virus vaccines had been
used in these countries and whether they were SV40-con-
taminated or not.
Methods
Study design
We conducted a Medline search for the period from Janu-
ary 1969 to August 2005 with use of the following terms
and Boolean operators: (("SV40" OR "simian virus 40")
AND ("tumor" OR "tumour" OR "cancer")) or (("SV40"
OR "simian virus 40") AND (" [country]" OR " [country
language]")) or (("SV40" OR "simian virus 40") AND
("Europe*")). All abstracts were checked for valid results
on SV40 DNA in human tissue samples or for information
about past poliomyelitis virus vaccination programs in
European countries. The bibliography of each paper was
then further screened by two researchers for additional
relevant studies.
Inclusion and exclusion criteria for molecular genetic 
studies
Articles were independently examined in detail by two
investigators (A.L. and K.L.). All studies on SV40 in
human tissue samples (mostly tumors) or body fluids
derived from a European country were considered for
analysis. Eligibility criteria: Only original articles on SV40
detection were included. The origin of the samples had to
be clearly stated. As an inclusion criterion, SV40 nucleic
acid hybridization or polymerase chain reaction (PCR)
methods had to be performed for SV40 detection. Studies
on cell lines were not included. One study was excluded
because the SV40-positive patient was the newborn child
of foreign guest workers [29]. In one study from Berlin,
the origin of the patients was not clear (Western or Eastern
Germany), the study was therefore excluded [30]. One
study with data on SV40 DNA in sewage from two Euro-
pean cities was excluded from the analysis [31]. Although
SV40 may be shed in stool [32] the implications of these
data are unclear since comparable studies are missing. The
relevant data from of the eligible studies were abstracted
by one researcher and rechecked for accuracy by another.
In particular, we extracted the following information: ori-
gin of the tissue specimen, tumor or non-tumor tissue,
type of tumor, number of SV40-positive samples, number
tested, and detection method.
Inclusion and exclusion criteria for reports on SV40 in 
vaccines
All reports retrievable from the Medline search or from the
bibliography of each paper containing data on SV40 con-
tamination of vaccines used in a specific European coun-
try were eligible for analysis.
Mesothelioma mortality data
In the absence of a specific International Classification of
Diseases [ICD] code for mesothelioma until the introduc-
tion of a specific code for mesothelioma (C45) in the 10th
revision of the ICD in 1992 [33], pleural cancer (ICD 163)
death rates were used for the analysis. Mortality of pleural
cancer is mainly attributed to mesothelioma [34] and cor-
responds reasonably with mesothelioma incidence, since
most patients diagnosed with mesothelioma will die
within one year [3]. For each country, age-standardized
(world standard population) pleural cancer mortality
rates were extracted from the World Health Organization
(WHO) database [35]. Mortality data from 1985 to 1989
were used because of the unification or division of some
European countries after the end of the Cold War (about
1989), in order to allow correlation with former country-
wide asbestos consumption data. To allow comparability,
the WHO database [35] was the only source of pleural
cancer mortality/incidence data used. Cancer incidence
rates are known to have been underestimated until 1992
in Belgium (DeVuyst, Hopital Erasme, Brussels, personal
communication and [36]), therefore, in the case of Bel-
gium, pleural cancer mortality from 1995 to 1999 was
retrieved from the WHO mortality database [33] and was
compared to asbestos consumption in 1970 in Belgium-
Luxembourg. Since data from Turkey were not retrievable
from the WHO database [35], Turkish mesothelioma inci-
dence in 1996, as reported by Menintas et al. [37], was cor-
related with asbestos consumption in 1970.
Asbestos consumption data
Asbestos consumption data were provided by the U.S.
Geological Survey, Reston, VA [10]. For some countries,
the information about either asbestos or pleural cancer
mortality was unfortunately incomplete: these data were
therefore excluded from further analysis.
Statistical analysis
For statistical analyses, the NCSS 2001 (NCSS Statistical
Systems, Kaysville, UT, USA) software package was used.
P < 0.05 was considered to be significant. The Spearman's
correlation coefficient was calculated for the following
variables: male/female pleural cancer mortality and asbes-
tos consumption. ANCOVA was used for group compari-
sons with past asbestos consumption as a covariate, and
male/female pleural cancer mortality as a dependent vari-
able. No adjustment for multiple testing was done.
Results
Mesothelioma and asbestos
When we correlated male pleural cancer death rates in 18
European countries with per capita asbestos consumption
25 to 30 years earlier, we found a linear relationship (Fig-
ure 1). The Spearman's correlation coefficient of the two
variables is R = 0.603 (P = 0.008). Notably, all EuropeanOrphanet Journal of Rare Diseases 2006, 1:44 http://www.OJRD.com/content/1/1/44
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countries with available information on asbestos con-
sumption and pleural cancer mortality were included in
the analysis (the sources are indicated in the methods sec-
tion). For females, no linear relationship could be demon-
strated (Figure 2). The Spearman's correlation coefficient
of the two variables is R = 0.293 (P = 0.239).
SV40 data
According to our criteria, 55 original articles on SV40 in
human tissue samples or body fluids derived from 13
European countries contained information relevant to our
analysis (Figures 3 and 4, Table 1). For all countries except
the U.K., data for pleural cancer mortality and past asbes-
tos use were available. Thus, 12 countries were included in
the statistical analysis. The cut off level for SV40 detection
was set at 0% or 10% positive tumor samples, respectively
(Figure 3). Before analyzing the effect of SV40 prevalence,
we corrected male pleural cancer rates for asbestos con-
sumption because these two variables are highly corre-
lated. However, whether SV40 DNA had been detected in
tumor samples from a particular country or not, had no
effect on pleural cancer mortality rates at either cut-off
level, neither in males (asbestos-corrected rates) nor in
females (Table 2).
Poliomyelitis virus vaccines
Information regarding the type of poliomyelitis virus vac-
cine (and whether it had been SV40-contaminated or not)
was eligible from 15 countries (Table 3). In ten countries,
the usage of SV40-contaminated polio vaccines is unam-
biguously documented, while in three other countries
SV40-contaminated vaccines had apparently not been
used (Table 3, Figure 4). For Spain and Poland, contradic-
tory reports exist (Table 3). For ten countries with either
positive or negative SV40 contamination of vaccines, data
on asbestos consumption and pleural cancer were availa-
ble (see Figure 1, sources are indicated in the methods sec-
tion). Our statistical analyses revealed that whether the
polio vaccine was contaminated or not, had no impact
whatsoever on male asbestos consumption-corrected or
female pleural cancer rates. In males, the mean asbestos-
corrected mortality rate was 0.77/100 000 (n = 7) in coun-
tries with SV40-contaminated vaccines and 0.83/100 000
(n = 3) in countries without SV40-contaminated vaccines
(P = 0.700). In females, the mean mortality rate was 0.24/
100 000 (n = 7) in countries with SV40-contaminated vac-
cines and 0.31/100 000 (n = 3) in countries without SV40-
contaminated vaccines (P = 0.377).
Per capita asbestos consumption and female pleural cancer  mortality rates in European countries Figure 2
Per capita asbestos consumption and female pleural cancer 
mortality rates in European countries. In the legend SV40 
detection refers to SV40 nucleic acid detection at a cut-off 
level of 10%.Per capita asbestos consumption in a state was 
calculated as the production plus imports minus exports of 
all types of asbestos (Data from U.S. Geological Survey).
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Correlation between per capita asbestos consumption and  male pleural cancer mortality rates (R = 0.603, P = 0.008) Figure 1
Correlation between per capita asbestos consumption and 
male pleural cancer mortality rates (R = 0.603, P = 0.008). In 
the legend SV40 detection refers to SV40 nucleic acid detec-
tion at a cut-off level of 10%. Per capita asbestos consumption 
in a state was calculated as the production plus imports 
minus exports of all types of asbestos (Data from U.S. Geo-
logical Survey).
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In addition, we analyzed the impact of the type of vaccine
(IPV or OPV) used between 1957 and 1963 on pleural
cancer rates in Europe. In two of the ten countries (Swe-
den and Finland), IPV was the only vaccine used at least
until 1996, in two other countries (Denmark and Nor-
way) OPV was used as well as IPV, but not before 1967,
when Western European vaccines were SV40 free. In four
countries, OPV was used between 1957 and 1963,
together with variable exposure to IPV. In one country
(Hungary) the predominant type of vaccine used between
1957 and 1963 is unclear, and in one country (Turkey)
apparently no vaccine has been used between 1957 and
1963. In countries with past use of contaminated IPV, the
mean male asbestos-corrected pleural cancer rate was
0.95/100 000 (n = 3), and was 0.77/100 000 (n = 5) in all
other countries (P = 0.381). In countries with past use of
contaminated OPV, the mean male asbestos-corrected
pleural cancer rate was 0.77/100 000 (n = 3) and was
0.87/100 000 (n = 5) in all other countries (P = 0.619). In
countries with past use of contaminated IPV, mean female
pleural cancer rate was 0.23/100 000 (n = 3) and was
0.28/100 000 (n = 5) in all other countries (P = 0.636). In
countries with past use of contaminated OPV, mean
female pleural cancer rate was 0.25/100 000 (n = 3) and
was 0.27/100 000 (n = 5) in all other countries (P  =
0.844). Therefore, we did not find any significant differ-
ences in pleural cancer rates from countries with past use
of SV40-contaminated IPV or OPV compared to the other
European countries.
Discussion
The main purpose of this ecological analysis was to
explore the potential effect of a country-wide presence of
SV40 on the respective pleural cancer mortality rate, pre-
suming that SV40 has the long adjudicated tumor-induc-
ing or -promoting role in humans. A country-wide
presence of SV40 was inferred from previous vaccination
programs with contaminated vaccines or the detection of
virus DNA in tumor samples. Although the results of our
analyses confirmed the previous well-established associa-
tion between the male pleural cancer mortality rate and
the extent of the asbestos consumption 25 to 30 years ear-
lier, we failed to detect any discernible effect on the
respective male or female pleural cancer mortality rates
that could have been allocated to SV40.
The oncogenic potential of SV40 and the mode of its
introduction into the human population via  contami-
nated vaccines are well documented (for review see [12]).
However, whether viral infection indeed also represents a
risk factor for tumor development in humans is still a
rather controversial issue, which at present is primarily
supported by spurious molecular genetic studies, but not
by firm epidemiological evidence [106]. However, even
the question of whether SV40 is actually present in human
tumors and if so, what role it might play in tumor devel-
opment, is currently unsolved and a matter of ongoing
debate, especially since two multi-center studies reached
different conclusions [107,108]. Epidemiological studies
about tumors developing in recipients of SV40-contami-
nated vaccines are mainly hampered by the fact that the
infected cohorts are difficult to identify, because SV40 has
been found in tumors of patients that were too young to
have been exposed to contaminated vaccines [4].
To differentiate between SV40-contaminated and SV40-
free European countries, we collected all eligible studies
dealing with this topic and extracted the relevant informa-
tion. However, we excluded all studies which had merely
used immunological and serological detection proce-
dures, because SV40 and the human BK and JC polyoma-
viruses are known to cross-react to a high degree [109-
113]. For the same reason, we also excluded reports that
dealt with serum antibodies against SV40. We were never-
theless able to identify three countries (Austria, Finland
and Turkey), in which exclusively SV40-free polio vac-
cines had been used. Incidentally, these were the same
countries in which molecular genetic studies failed to
Frequencies of SV40 nucleic acid detection in European  human tissue samples Figure 3
Frequencies of SV40 nucleic acid detection in European 
human tissue samples. Only reports using polymerase chain 
reaction or hybridization techniques were included. The 
original reports are cited in Table 1. Pleural cancer mortality 
data were not available for the entire United Kingdom, which 
was therefore excluded from statistical analysis.
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detect SV40 DNA in a representative large number of
tumor samples [19-24].
Although we were unable to find any epidemiological evi-
dence for a potential association between SV40 and pleu-
ral cancer, the following limitations of our analysis have
to be taken into consideration. First of all, we were unable
to account for different types and particular usage of
asbestos. Instead, we used the asbestos data from a single
source, the U.S. Geological Survey [10]. Naturally occur-
ring asbestos is found in soils or rocks in certain villages
in southeast Turkey, where it causes endemic occurrence
of mesothelioma [114], and also in other parts of the
world, e.g. in California [115]. However, it was not possi-
ble to correct for the impact of natural asbestos deposits
in the cohorts used in this study. Even if Turkey is
Map of SV40 nucleic acid detection and historical vaccine contamination with SV40 in European countries Figure 4
Map of SV40 nucleic acid detection and historical vaccine contamination with SV40 in European countries. For nucleic acid 
detection a cut-off level of 10% (SV40 positive samples from a country of total examined samples) was chosen.Orphanet Journal of Rare Diseases 2006, 1:44 http://www.OJRD.com/content/1/1/44
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excluded from the analysis, no significant association
between SV40 and pleural cancer is found, neither in
males (asbestos-corrected rates), nor in females (data not
shown).
Second, differences in cancer registration exist and
increasing diagnostic awareness in the past 20 years may
have affected the reported mortality rates. Miscoding
might have occurred in countries where only death certif-
icates were used for mesothelioma registration [34]. To
optimize comparability, we therefore used the WHO data-
base as our only source of information. In the majority of
cases, we used mortality data from 1985 to 1989. More
recent mortality rates from the WHO mortality database
would not allow comparability of mortality rates with
former country-wide asbestos consumption data because
of the unification or division of certain European coun-
tries after the end of the Cold War (about 1989). Data
from the International Agency for Research on Cancer
(IARC) database [116] were not suitable, because for
many countries the incidence rates are indicated on a dis-
trict-basis only, and not in a country-based fashion. How-
ever, the important limitation of possibly incorrect
pleural cancer rates could not be overcome in the current
study. Therefore, improvements in cancer registration are
important for future studies addressing these questions.
Third, methodological differences in SV40 screening pro-
cedures (e.g. different PCR primers, frozen versus paraffin
embedded tissues) lead to unequal sensitivities [117]. An
unknown proportion of positive SV40 DNA results may
have been related to contamination or to other problems
with the PCR methods [118]. Optimized laboratory pro-
cedures for SV40 detection have been only recently
defined [119]. However, as is suggested, mostly by the
laboratory investigators themselves, there might be a rela-
tionship between country-specific PCR results and geo-
graphic variations in SV40 occurrence [4] and hence
mesothelioma incidence. Therefore, to study geographic
variations, we chose to assume the accuracy of the prior
positive PCR results. The different sample sizes of the
SV40 detection studies were taken into account by assess-
Table 2: Comparison of pleural cancer mortality rates in countries with or without molecular genetic evidence of SV40
Category Cut-off level Mean pleural cancer mortality in SV40-nucleic acid 
positive countries (/100 000/yr)
Mean pleural cancer mortality in SV40-nucleic acid 
negative countries (/100 000/yr)
P
Males* 0% 0.97 (n = 9) 0.81 (n = 3) 0.465
Females 0% 0.31 (n = 9) 0.31 (n = 3) 0.956
Males* 10% 1.04 (n = 8) 0.69 (n = 4) 0.082
Females 10% 0.33 (n = 8) 0.28 (n = 4) 0.397
Cut-off level refers to the percentage of SV40-positive human tissue samples of all samples tested in a country. *Asbestos-corrected rates.
Table 1: SV40 nucleic acid detection in human samples
Country Positive reports on SV40 nucleic acids Negative reports on SV40 
nucleic acids
SV40 detection at 0% cut-
off level
SV40 detection at 10% cut-
off level
Austria [21,22] - -
Belgium [38,39] [40,41] + +
Finland [19,23] - -
France [42] [41,43] + +
Germany West [44-51] [52-54] + +
Germany East [55] + +
Hungary [51] + +
Italy [14,17,47,56-70]a [71-73] + +
Spain [74] low positive [71,75]b +-
Sweden [76] + +
Switzerland [77] data also presented in [23] + +
Turkey [20,24] - -
United Kingdomc [78-81] [82-85] + +
Total number of 
studies
37 18
Percent cut-off level refers to percentage of SV40-positive human tissue samples in all samples tested in a country.
aHealthy subjects were tested in [70].
bOne study [75] contained only uterine cervix carcinoma samples.
cPleural cancer mortality data were available only for England and Scotland, but not for the entire U.K., therefore the U.K. was excluded from 
further statistical analysis.Orphanet Journal of Rare Diseases 2006, 1:44 http://www.OJRD.com/content/1/1/44
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ing the number of samples with positive SV40 nucleic acid
detection versus the whole number analyzed samples for
each eligible study. Further issues that also have to be con-
sidered in such analyses are, of course, that potential but
yet undefined specific genetic factors might influence the
likelihood of mesothelioma development in different
populations [120].
In the United States, a potentially contaminated poliomy-
elitis virus vaccine was used between 1955 and 1963
nationwide on about 90% of children and 60% of adults
[16,121]. In Europe, approximately 60% of the popula-
tion received a potentially contaminated vaccine [121].
However, the SV40 prevalence in many European coun-
tries is more mosaic-like, because it still mirrors the pat-
tern of when and with which vaccine mass vaccination
programs were initiated by local governments. At the
beginning of our investigation, we were confident that we
could obtain the necessary SV40 data from the vaccine
producing companies, which would have been the most
efficient and accurate way of determining the pattern of
use of contaminated vaccines. However, many of our
requests remained unanswered and in some instances the
relevant information had apparently already been
destroyed, unclear statements were frequent. Therefore,
national health bulletins (like those issued in Austria and
Spain) became a particularly important resource
[91,92,101]. Reports on historical SV40 contamination of
vaccines may be of varying accuracy, depending on the
detection methods used and on the number and source of
samples (batches) tested. However, all data were assumed
to be of equal weight because weighting of such heteroge-
nous data was not possible. Moreover, other routes of
transmission may exist. Epidemiological evidence sug-
gests that SV40 may be contagiously transmitted in
humans by horizontal infection, independent of the ear-
lier administration of SV40-contaminated polio vaccines
[113]. Recently, even infection through laboratory strains
of SV40 has been proposed [122].
Although little is known about the severity of SV40 infec-
tion in humans (systemic or non-systemic), some data
indicate that there might be biological differences
depending on the type of exposure (IPV vs. OPV). After
oral administration of SV40 in humans, there was no anti-
body response, indicating that it most likely did not result
in systemic infection, which would most likely be neces-
sary for cancer induction (for review see [88]). On the
other hand, after subcutaneous inoculation of SV40-con-
taminated inactivated vaccines, antibody titers were high
and remained high or declined slightly over a 3-year fol-
low-up [88]. After 1961, IPV was replaced in many coun-
Table 3: SV40 in poliomyelitis virus vaccines in European countries
Country Rating of contamination of
polio vaccines with SV40
Vaccines, vaccination programs and origin of vaccines
Albania Positive Contaminated Russian vaccine (OPV) used since 1960 [86-90].
Austria Negative Mass vaccinations with SV40-free British vaccine (OPV) since winter 1961/62 [91-92].
Bulgaria Positive Contaminated Russian vaccine (OPV) used since 1960 [86-90].
CSSR Positive Since 1960: limited use of IPV, mass vaccinations with OPV, partly with contaminated Russian 
vaccine [86-90,93-94].
Denmark Positive Vaccinations from 1955 with widely contaminated Danish vaccine (IPV), SV40-free from 1963 [95]. 
A combined schedule was introduced in 1968 [96].
Finland Negative Mass vaccinations since 1957 with SV40-free Belgium vaccine (IPV) [19]. Finland has never used 
OPV on a routine basis [96].
Germany East Positive Contaminated Russian vaccine (OPV) used since 1960 [55, 87-90, 97].
Hungary Positive Since 1957: limited use of IPV, mass vaccinations with vaccines from the US, Canada, Hungary and 
Russia (also OPV) [87-90].
Norway Positive Vaccinations started 1956 with Danish vaccine (IPV); since 1957 potentially contaminated U.S. 
vaccine (IPV) [98], change to OPV from 1967 to 1979, then back to IPV from 1979 onwards [96].
Poland Unclear Mass vaccinations (OPV) since 1958 with Koprowski strain live vaccine [94]; vaccine was claimed to 
be Russian made [99], but Russian vaccines were derived from Sabin's strain [86].
Russia (USSR) Positive Mass vaccinations since 1959 with contaminated Russian vaccine (OPV). A small proportion of 
persons were vaccinated with IPV at the beginning of the mass vaccinations. [86-90, 100].
Spain Unclear Mass vaccinations since 1963 with British vaccine (OPV) [101]; British vaccines were SV40-free 
since 1962 [102]; in contrast some vaccines were later claimed to have been contaminated [103].
Sweden Positive In 1957 potentially contaminated U.S. vaccine (IPV), from 1958 SV40-free Swedish vaccine (IPV). 
Sweden has never used OPV [96].
Turkey Negative Vaccination was not started before 1970, at a time where polio vaccines were required to be SV40-
free [20, 24]. The type of the vaccine is unclear. In a global poliomyelitis eradication initiative 
starting in 1989, OPV was used.
United Kingdom Positive Vaccination started in 1956 with OPV [104-105]. SV40-free since 1962 [102].
CSSR: Czechoslovak Socialist Republic; OPV: oral polio vaccine; IPV: inactivated polio vaccine.Orphanet Journal of Rare Diseases 2006, 1:44 http://www.OJRD.com/content/1/1/44
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tries by OPV, although a few continued to use IPV and
others subsequently reintroduced it. We identified four
countries that used only IPV between 1957 and 1963 and
recalculated differences in mean pleural cancer rates tak-
ing into account the type of vaccine used in the country.
However, whether SV40-contaminated OPV or IPV was
used in a specific country had no impact on asbestos-cor-
rected (male) or raw (female) pleural cancer rates. Many
countries used IPV to a variable extent before mass vacci-
nations with OPV. Unfortunately, hardly any information
about these vaccination programs remains available.
Therefore, the level of exposure to IPV could not be exactly
determined for every country.
We used two different approaches to analyze the associa-
tion between SV40 prevalence and pleural cancer mortal-
ity in European countries. First, we used data on historical
SV40 exposure. However, the infected cohorts are diluted
by individuals not vaccinated during the possible time of
infection or vaccinated with SV40-free vaccines. Second,
we screened the literature for molecular genetic evidence
of SV40 in tumor samples from the different countries.
The methods applied would detect only a strong carcino-
genic or co-carcinogenic effect of SV40 on the pleura (in
males aggregated by country) because of the crude adjust-
ments for asbestos consumption, without distinguishing
between chrysotile and amphibole asbestos. However, the
results of this study, the negative SV40 DNA reports, and
the serologic data argue against a major role of SV40 in
mesothelioma carcinogenesis.
Conclusion
Finally, despite all the shortcomings and problems, our
comprehensive data collection provides the first account
of the diverse usage of different types of poliomyelitis
virus vaccines from all available data from European
countries. In conjunction with the records obtained from
the molecular genetic screening for SV40 DNA in tumor
samples derived from the respective populations, it pro-
vides the best achievable distribution map available to
date on SV40 prevalence in Europe and the basis for future
reassessments of epidemiological SV40 data, whenever
new information becomes available. This ecological anal-
ysis makes an association of male pleural cancer with
SV40 unlikely, but this needs to be confirmed by case con-
trol studies and cohort studies.
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